Oral Session 1-12D ALL: Clinical Trials

[OS1-12D-1] Update results of Hyper-CVAD with ponatinib for newly diagnosed Ph+ ALL - a phase 2 Study

Koji Sasaki¹, Hagop Kantarjian¹, Farhad Ravandi¹, Nicholas Short¹, Naval Daver¹, Naveen Pemmaraju¹, Deborah Thomas¹, Musa Yilmaz¹, Tapan Kadia¹, Rebecca Garris¹, Guillermo Garciamanero¹, Courtney Dinardo¹, Marina Konopleva¹, Zeev Estrov¹, Jain Nitin¹, William Wierda¹, Vicki Jeanis¹, Jorge Cortes¹, Susan Obrien², Elias Jabbour¹ (1.Houston, TX, U.S.A., 2.University of California, Irvine, CA, U.S.A.)